Editas Medicine Inc (OQ:EDIT)

Business Focus: Biotechnology & Medical Research

Feb 28, 2024 07:00 am ET
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates. “I am proud of our team’s execution in 2023 as we made...
Feb 21, 2024 07:00 am ET
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year...
Jan 31, 2024 09:00 am ET
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:...
Jan 08, 2024 08:15 am ET
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, will discuss the Company’s 2024 strategic priorities and anticipated...
Jan 03, 2024 07:00 am ET
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday,...
Dec 13, 2023 09:00 am ET
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement. Under terms of the agreement, Vertex will obtain a non-exclusive license...
Dec 11, 2023 12:00 pm ET
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced new safety and efficacy data in 17...
Nov 03, 2023 07:00 am ET
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates. “We made significant progress advancing EDIT-301 in the third quarter,...
Nov 02, 2023 09:12 am ET
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and...
Oct 27, 2023 07:00 am ET
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide...
Oct 16, 2023 08:00 am ET
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene...
Sep 25, 2023 04:30 pm ET
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms....
Sep 25, 2023 09:00 am ET
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s...
Aug 30, 2023 09:00 am ET
Editas Medicine Announces Upcoming Investor Events
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences: 2023 Wells Fargo Healthcare ConferenceFormat: Fireside...
Aug 28, 2023 07:00 am ET
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will...
Aug 02, 2023 07:00 am ET
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the second quarter 2023 and business updates. “We continued making significant progress against our strategic plan in the...
Jul 27, 2023 09:00 am ET
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 /PRNewswire/ -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine's experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), from approval to commercialization.  The expanded agreement includes compliant cleanroom space and labs se
Jul 27, 2023 09:00 am ET
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have expanded their multi-year contract to support the scaling of EDIT-301,...
Jul 26, 2023 07:00 am ET
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 2, 2023, at 8:00 a.m. ET to discuss results for the second quarter 2023 and to...
Jul 25, 2023 08:00 am ET
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Scientific Officer, Linda C. Burkly, Ph.D. In connection with Dr. Burkly’s...
Jul 24, 2023 07:00 am ET
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas’ drug...
Jun 14, 2023 10:06 pm ET
Editas Medicine Announces Pricing of Offering of Common Stock
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting...
Jun 14, 2023 04:05 pm ET
Editas Medicine Announces Offering of Common Stock
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the...
Jun 09, 2023 03:00 am ET
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients achieved normal levels of total hemoglobin and fetal...
Jun 06, 2023 08:00 am ET
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June 12, at 8:00 a.m. ET to present clinical data from the RUBY trial of EDIT-301 for the treatment of severe...
May 18, 2023 04:30 pm ET
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Erick Lucera. In connection with Mr. Lucera’s appointment, the...
May 16, 2023 04:30 pm ET
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer, effective May 17, 2023. Mr. Lucera will succeed Michelle...
May 11, 2023 10:32 am ET
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the Phase 1/2 RUBY trial of EDIT-301 in patients with severe sickle cell...
May 05, 2023 07:00 am ET
Editas Medicine Announces First Quarter 2023 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the first quarter 2023. “I am energized by our strong start to the year. We entered 2023 with the...
May 01, 2023 04:01 pm ET
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK (SeLection by Essential-gene Exon Knock-in)...
May 01, 2023 06:45 am ET
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 and to provide a...
Apr 27, 2023 09:00 am ET
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the...
Apr 13, 2023 09:00 am ET
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently...
Mar 08, 2023 09:00 am ET
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer. Ms. Aspesi will lead Editas’ human resources...
Feb 22, 2023 06:15 am ET
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2022. “I’m proud of our team’s achievements in 2022, as we showed...
Feb 15, 2023 06:45 am ET
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 22, 2023, at 8:00 a.m. ET to discuss results for the fourth quarter and full year...
Jan 19, 2023 07:00 am ET
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK...
Jan 09, 2023 08:15 am ET
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced a strategic update, including portfolio reprioritization and research and development realignment. The Company’s R&D efforts will narrow, focusing on...
Jan 04, 2023 06:30 am ET
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday,...
Dec 06, 2022 06:30 am ET
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced positive, initial clinical data from the first two patients with sickle cell disease (SCD) treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is...
Dec 01, 2022 04:01 pm ET
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of EDIT-301,...
Nov 17, 2022 07:15 am ET
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine in a Company-sponsored webinar. EDIT-101 is...
Nov 02, 2022 06:30 am ET
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the third quarter of 2022. “I am pleased with our continued progress, and I look forward to providing...
Oct 26, 2022 06:30 am ET
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and results for the third...
Oct 13, 2022 06:00 am ET
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced ex vivo and in vivo preclinical data supporting its experimental medicine EDIT-103 for the treatment of rhodopsin-associated autosomal dominant retinitis...
Sep 01, 2022 06:30 am ET
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference Format: Fireside ChatDate: Wednesday,...
Aug 03, 2022 06:29 am ET
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2022. “Since joining Editas Medicine two months ago, my review of the innovative...
Jul 27, 2022 06:30 am ET
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the dosing and confirmed successful neutrophil and platelet engraftment of the first patient in the Phase 1/2 RUBY trial of EDIT-301 for the treatment of severe...
Jul 26, 2022 06:26 am ET
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corporate updates for the second...
Jul 20, 2022 04:30 pm ET
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Baisong Mei, M.D., Ph.D. In connection with Dr. Mei’s appointment, the...
Jul 18, 2022 07:00 am ET
Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company’s Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical...
Jun 07, 2022 07:00 am ET
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome...
Jun 06, 2022 04:30 pm ET
Editas Medicine Reports Inducement Grants to New Chief Executive Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed President and Chief Executive Officer, Gilmore O’Neill, M.B., M.M.Sc. As previously announced,...
May 18, 2022 06:45 am ET
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present data later today on its SLEEK (SeLection by Essential- gene Exon Knock-in) gene editing technology during the New Gene Editing Technologies and Applications...
May 12, 2022 04:30 pm ET
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the treatment of...
May 04, 2022 01:30 pm ET
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced ex vivo and in vivo preclinical data for its experimental medicine EDIT-103 for the treatment of rhodopsin-associated autosomal dominant retinitis pigmentosa...
May 04, 2022 06:45 am ET
Editas Medicine Announces First Quarter 2022 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2022. “I am delighted with the appointment of Gilmore O’Neill as our incoming CEO,” said...
May 02, 2022 04:31 pm ET
Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25th Annual Meeting of the American Society of Gene and Cell...
Apr 27, 2022 06:55 am ET
Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of...
Apr 26, 2022 09:00 am ET
Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the...
Apr 14, 2022 07:30 am ET
Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has appointed Dr. Gilmore O’Neill, M.B., M.M.Sc., as President and Chief Executive Officer. James C. Mullen will serve as Executive...
Apr 11, 2022 09:00 am ET
Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient enrolled in the BRILLIANCE clinical trial, which is...
Apr 08, 2022 01:00 pm ET
Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced in vitro and in vivo preclinical data on the enhanced tumor killing capacity of modified induced pluripotent stem cell (iPSC)-derived natural killer (or iNK)...
Mar 01, 2022 07:35 am ET
Thinking about buying stock in CTI BioPharma, 3D Systems, Atea Pharmaceuticals, Editas Medicine, or Mullen Automotive?
NEW YORK, March 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTIC, DDD, AVIR, EDIT, and MULN.
Feb 28, 2022 04:01 pm ET
Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to the Broad Institute, Inc. (Broad) involving specific patents for CRISPR/Cas9...
Feb 24, 2022 06:30 am ET
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2021. “We’re entering 2022 with an expanded pipeline of clinical programs and...
Feb 16, 2022 06:15 am ET
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter...
Jan 10, 2022 07:00 am ET
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James C. Mullen, Chairman, President, and Chief Executive Officer, will discuss the Company’s recent progress and outlook for its gene editing medicines...
Jan 04, 2022 06:58 am ET
Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at...
Dec 20, 2021 08:32 am ET
Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights’ Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is...
Dec 20, 2021 07:00 am ET
Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling...
Dec 12, 2021 06:00 pm ET
Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported in vitro and in vivo preclinical data on the enhanced tumor killing capacity of two modified induced pluripotent stem cell (iPSC)-derived natural killer (or iNK)...
Nov 12, 2021 07:00 am ET
Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data on its progress in the development of novel engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells (or iNKs) for the...
Nov 08, 2021 07:00 am ET
Editas Medicine Announces Third Quarter 2021 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2021. “Editas recently marked an important milestone with the presentation of initial...
Nov 04, 2021 09:02 am ET
Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH), being...
Oct 28, 2021 09:00 am ET
Editas Medicine Names Bernadette Connaughton to Board of Directors
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors. Ms. Connaughton is an accomplished pharmaceutical executive with more than 30 years of...
Oct 25, 2021 04:01 pm ET
Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 8, 2021, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of...
Oct 20, 2021 09:00 am ET
Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the 2021 European...
Oct 07, 2021 08:00 am ET
Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for...
Sep 30, 2021 08:00 am ET
Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present at Chardan’s 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET. A live webcast of the presentation will be available on the...
Sep 29, 2021 09:00 am ET
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced positive initial clinical data from the ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101. EDIT-101 is under development for the treatment of...
Sep 13, 2021 08:00 am ET
Aadi Bioscience Appoints Emma Reeve to its Board of Directors
Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its...
Sep 08, 2021 09:00 am ET
Editas Medicine Names Emma Reeve to Board of Directors
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of Directors. Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global...
Sep 07, 2021 04:00 pm ET
Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth...
Sep 02, 2021 08:00 am ET
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: Wells Fargo 2021 Virtual Healthcare ConferenceFireside Chat (Virtual)Date:...
Aug 23, 2021 09:31 am ET
Thinking about trading options or stock in BioNTech, Xilinx, Editas Medicine, MicroStrategy, or Exxon Mobil?
NEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNTX, XLNX, EDIT, MSTR, and XOM.
Aug 20, 2021 04:20 pm ET
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced data on a new gene editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). The Company reported these data in an oral presentation at Cold...
Aug 09, 2021 09:31 am ET
Thinking about trading options or stock in MicroStrategy, Editas Medicine, DraftKings, Tyson Foods, or Apple?
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSTR, EDIT, DKNG, TSN, and AAPL.
Aug 04, 2021 07:00 am ET
Editas Medicine Announces Second Quarter 2021 Results and Business Updates
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2021. “We continue to make exciting progress on our clinical and preclinical programs,...
Jul 29, 2021 09:00 am ET
Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Pot
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Integrated DNA Technologies, Inc. (IDT), a leading comprehensive genomics research solutions provider, today announced the publication of research data demonstrating the...
Jul 28, 2021 07:00 am ET
Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 4, 2021, at 8:00 a.m. ET to provide a corporate update and results for the second quarter...
Jul 26, 2021 09:00 am ET
Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that Bruce E. Eaton, Ph.D., has been promoted to Executive Vice President and Chief Business Officer. In his new role, Dr. Eaton oversees the Company’s...
Jun 28, 2021 09:31 am ET
Thinking about trading options or stock in Intellia Therapeutics, Editas Medicine, Virgin Galactic, Microsoft, or Baidu?
NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NTLA, EDIT, SPCE, MSFT, and BIDU.
Jun 23, 2021 07:00 am ET
Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that centers are now enrolling the first of two planned pediatric cohorts in the Phase 1/2 BRILLIANCE clinical trial of EDIT-101 following the Independent Data...
Jun 15, 2021 04:01 pm ET
Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice...
Jun 14, 2021 09:00 am ET
Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Chi Li, Ph.D., MBA, RAC, as the Company’s Senior Vice President and Chief Regulatory Officer, effective immediately. Dr. Li will lead regulatory...
Jun 11, 2021 06:00 am ET
Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congre
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data supporting the initiation of the EDIT-301 Phase 1/2 RUBY clinical trial to evaluate EDIT-301, a one-time, durable, autologous cell therapy...
May 05, 2021 07:00 am ET
Editas Medicine Announces First Quarter 2021 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and...
May 05, 2021 06:59 am ET
Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June...
May 04, 2021 09:00 am ET
Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therap
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held virtually...
May 01, 2021 07:11 am ET
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophth
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held...
Apr 28, 2021 07:01 am ET
Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 5, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of...
Feb 25, 2021 07:00 am ET
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2020. “Editas has a once-in-a-generation technology enabling us to develop...
Feb 18, 2021 04:02 pm ET
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the fourth quarter...
Feb 08, 2021 08:00 am ET
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mullen will continue as Chairman of...
Jan 20, 2021 10:30 pm ET
Editas Medicine Announces Pricing of Offering of Common Stock
Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter...
Jan 19, 2021 04:01 pm ET
Editas Medicine Announces Offering of Common Stock
Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a...
Jan 11, 2021 06:05 am ET
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
In a presentation to investors on Wednesday, January 13 at 10:50 a.m. EST at the 39th Annual J.P. Morgan Healthcare Conference being held virtually, Editas Medicine, Inc. (Nasdaq: EDIT), President and Chief Executive Officer Cynthia Collins will...
Jan 11, 2021 06:02 am ET
Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the Company can begin...
Jan 11, 2021 06:00 am ET
Editas Medicine Announces Transition of Chief Scientific Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway...
Jan 04, 2021 04:05 pm ET
Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m. ET....
Dec 22, 2020 08:31 am ET
Thinking about trading options or stock in Apple, Peloton, FuelCell Energy, Editas Medicine, or Goldman Sachs?
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, PTON, FCEL, EDIT, and GS.
Dec 17, 2020 04:05 pm ET
Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors. Dr. Chatterjee is an accomplished biopharmaceutical executive with more than 30...
Dec 09, 2020 04:01 pm ET
Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDA
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical trial of...
Dec 05, 2020 10:00 am ET
Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data and successful development of a large-scale manufacturing process for EDIT-301, a potentially best-in-class, one-time, durable, autologous cell...
Nov 10, 2020 04:01 pm ET
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Medical Officer, Lisa Michaels, M.D. In connection with Dr....
Nov 09, 2020 04:05 pm ET
Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing & Gene Therapy Summit on Monday, November 16 at 10:15am ET. The event will be webcast live and may be...
Nov 09, 2020 09:00 am ET
Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company’s Executive Vice President and Chief Medical Officer, effective immediately. Dr. Michaels will lead...
Nov 05, 2020 04:02 pm ET
Editas Medicine Announces Third Quarter 2020 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2020. “We were pleased to regain full operating control of our ocular programs per our new...
Oct 29, 2020 04:01 pm ET
Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, November 5, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter...
Oct 01, 2020 08:00 am ET
Editas Medicine to Participate in Upcoming Investor Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference: Chardan Virtual 4th Annual Genetic Medicines ConferenceFireside ChatDate:...
Sep 11, 2020 07:00 am ET
Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of Vienna, Emmanuelle...
Sep 04, 2020 08:00 am ET
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual ConferencePanel: Innovation in Cell...
Aug 24, 2020 08:30 am ET
Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for EDIT-301, an experimental, autologous cell medicine,...
Aug 06, 2020 04:05 pm ET
Editas Medicine Announces Second Quarter 2020 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2020. “I am extremely proud of our recent progress, as we remain on track with...
Aug 06, 2020 04:01 pm ET
Editas Medicine Regains Full Global Rights to Ocular Medicines
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber...
Jul 29, 2020 08:00 am ET
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and...
Jul 27, 2020 04:01 pm ET
Editas Medicine Appoints Gad Berdugo as Chief Business Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has named Gad Berdugo as the Company’s Chief Business Officer. Mr. Berdugo will oversee the Company’s business and corporate development, alliance...
Jul 23, 2020 04:01 pm ET
Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, August 6, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of...
Jul 07, 2020 09:00 am ET
Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have entered a multi-year agreement for current Good Manufacturing Practice...
Jul 07, 2020 09:00 am ET
Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing
CAMBRIDGE, Mass. and WALTHAM, Mass., July 7, 2020 /PRNewswire/ -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have entered a multi-year agreement for current Good Manufacturing Practice (cGMP)-compliant cleanroom space for Editas Medicine in Azzur's Waltham site. Editas Medicine will utilize the space and Azzur's services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 in development for the treatment of
Jun 26, 2020 04:05 pm ET
Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the closing of its previously announced underwritten offering of 6,900,000 shares of its common stock at a public offering price of $31.25 per share, before...
Jun 23, 2020 09:48 pm ET
Editas Medicine Announces Pricing of Offering of Common Stock
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 6,000,000 shares of its common stock at a public offering price of $31.25 per share, before deducting underwriter...
Jun 23, 2020 04:21 pm ET
Editas Medicine Announces Offering of Common Stock
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriter a...
Jun 12, 2020 06:00 am ET
Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical, proof-of-concept study of EDIT-301. EDIT-301 is being developed as a potentially best-in-class, durable medicine to treat sickle...
May 15, 2020 09:20 am ET
Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its proprietary engineered CRISPR-Cas12a (EngCas12a) in induced...
May 07, 2020 07:00 am ET
Editas Medicine Announces First Quarter 2020 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2020. “The COVID-19 pandemic has given rise to unprecedented circumstances for Editas and the...
Apr 30, 2020 08:05 am ET
Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of...
Apr 29, 2020 09:00 am ET
Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the initiation of IND-enabling activities for EDIT-201, an allogeneic natural killer (NK) cell medicine for the treatment of solid tumor cancers.  “We have...
Mar 04, 2020 05:00 am ET
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587...
Feb 26, 2020 04:02 pm ET
Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2019. “We are entering 2020 with strong momentum and a strategic focus on driving...
Feb 19, 2020 04:02 pm ET
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 26, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the fourth...
Jan 13, 2020 09:00 am ET
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
In a presentation to investors on Wednesday, January 15, 2020, at 10:30 a.m. PST at the 38th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (Nasdaq: EDIT) President and CEO Cynthia Collins will discuss the Company’s progress on...
Jan 13, 2020 08:55 am ET
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a strategic research collaboration, license, and option agreement to combine their respective...
Jan 10, 2020 04:30 pm ET
Editas Medicine Reports Inducement Grants to New Chief Financial Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Chief Financial Officer, Michelle Robertson. In connection with Ms. Robertson’s appointment, the...
Jan 09, 2020 09:00 am ET
Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Michelle Robertson as the Company’s Chief Financial Officer, and the appointment of Harry Gill in the newly created role of Senior Vice...
Jan 02, 2020 09:00 am ET
Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15,...
Dec 09, 2019 06:00 pm ET
Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and...
Nov 12, 2019 07:02 am ET
Editas Medicine Announces Third Quarter 2019 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2019. "Our momentum in 2019 remains strong in advancing our pipeline of in vivo CRISPR and...
Nov 12, 2019 07:00 am ET
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced an amended collaboration with Celgene Corporation (Nasdaq: CELG) under which the parties may research, develop, and commercialize autologous and allogeneic...
Nov 05, 2019 08:00 am ET
Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, November 12, 2019, at 8:00 a.m. ET to discuss a corporate update and results for the third quarter...
Oct 28, 2019 06:55 pm ET
Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Judith R. Abrams, M.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Abrams is a leading drug development clinician who has...
Oct 15, 2019 06:15 pm ET
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Asklepios BioPharmaceutical, Inc. (AskBio), a fully integrated adeno-associated virus (AAV) gene therapy company, today announced the companies have entered a strategic...
Oct 07, 2019 07:00 am ET
Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use...
Oct 01, 2019 08:00 am ET
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:  Cell & Gene Meeting on the MesaPanel: What does the future hold for gene...
Aug 29, 2019 08:00 am ET
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following investor conferences in September:  Citi 14th Annual Biotech ConferenceFormat: Hematology PanelDate:...
Aug 12, 2019 04:05 pm ET
Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines, today announced Andrew A. F. Hack, M.D., Ph.D., a Managing Director at  Bain Capital Life Sciences, has been appointed to...
Aug 06, 2019 04:15 pm ET
Editas Medicine Announces Second Quarter 2019 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2019. "I am pleased and honored to be appointed CEO at this exciting time for the company,"...
Aug 06, 2019 04:01 pm ET
Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has unanimously appointed Cynthia (Cindy) Collins, a 30-plus year industry veteran currently serving as the Company’s interim CEO as...
Jul 30, 2019 04:02 pm ET
Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, August 6, 2019, at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of...
Jul 25, 2019 09:00 am ET
Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the Brilliance Phase 1/2 clinical trial of AGN-151587 (EDIT-101) is open for patient...
Jun 15, 2019 11:30 am ET
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a follow-up study to assess two different CRISPR genome editing strategies, one targeting the BCL11A erythroid enhancer (BC11Ae) and one targeting...
May 07, 2019 04:01 pm ET
Editas Medicine Announces First Quarter 2019 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2019. "2019 is off to a strong start with tangible progress on multiple fronts," said Cynthia...
Apr 30, 2019 04:01 pm ET
Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, May 7, 2019, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of...
Apr 29, 2019 09:19 am ET
Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10)
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced initial data from the ongoing natural history study to evaluate patients with Leber congenital...
Apr 03, 2019 07:00 am ET
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and BlueRock Therapeutics, LP, a leading engineered cell therapy company, today announced a strategic research collaboration and cross-licensing agreement to combine their...
Mar 26, 2019 07:10 am ET
Research Report Identifies Spirit Airlines, Integrated Device Technology, Editas Medicine, MACOM Technology Solutions, Taylor Morrison Home, and Brunswick with Renewed Outlook — Fundamental Analysis,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Spirit Airlines, Inc. (NYSE:SAVE), Integrated Device Technology, Inc....
Feb 28, 2019 04:01 pm ET
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2018. “2018 was a year of significant achievements for Editas Medicine as we...
Feb 28, 2019 09:00 am ET
Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day®
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million Americans living with a rare disease and health care advocates around the world to help elevate...
Feb 21, 2019 04:02 pm ET
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter...
Feb 06, 2019 09:00 am ET
Editas Medicine Names David Scadden, M.D., to Board of Directors
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board of Directors, effective immediately. Dr. Scadden is a hematologist/oncologist and an expert on the...
Jan 24, 2019 07:35 am ET
Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, An
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SeaWorld Entertainment, Inc. (NYSE:SEAS), Rigel Pharmaceuticals, Inc....
Jan 22, 2019 09:00 am ET
Editas Medicine Announces Chief Executive Officer Transition
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Katrine Bosley has decided to step down from her role as President and CEO, effective March 1, 2019. Ms. Bosley also resigned from the Company’s Board of...
Jan 21, 2019 11:00 am ET
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity of EDIT-101, an experimental, CRISPR...
Jan 07, 2019 09:00 am ET
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
In a presentation to investors on Wednesday, January 9, 2019, at 9:00 a.m. PST at the 37th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (Nasdaq: EDIT) President and CEO Katrine Bosley will discuss the Company’s plans to initiate...
Jan 02, 2019 08:30 am ET
Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9,...
Dec 21, 2018 09:00 am ET
Editas Medicine Announces Transition of Chief Financial Officer
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D., Ph.D., will be stepping down from the Company, effective March 1, 2019, to return to the investment...
Dec 10, 2018 09:00 am ET
Editas Medicine Names Cynthia Collins to Board of Directors
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors. Ms. Collins is a recognized leader in cell and gene therapy, molecular diagnostics, life...
Dec 02, 2018 07:35 pm ET
Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of sickle cell disease and...
Nov 30, 2018 07:30 am ET
Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for EDIT-101, an experimental CRISPR genome...
Nov 12, 2018 08:30 am ET
Analysis: Positioning to Benefit within IDEXX Laboratories, Editas Medicine, Arconic, Cardtronics, Cloudera, and BMC Stock — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IDEXX Laboratories, Inc. (NASDAQ:IDXX), Editas Medicine, Inc....
Nov 07, 2018 04:01 pm ET
Editas Medicine Announces Third Quarter 2018 Results and Update
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter ended September 30, 2018. In addition, the Company highlighted select corporate milestones and...
Oct 31, 2018 04:01 pm ET
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 7, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter...
Oct 18, 2018 09:15 am ET
Recent Analysis Shows Lantheus, Editas Medicine, CorMedix, DXP Enterprises, Peabody Energy, and CommScope Holding Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Lantheus Holdings, Inc. (NASDAQ:LNTH), Editas Medicine, Inc....
Oct 01, 2018 09:00 am ET
Editas Medicine Grows Scientific Leadership with Two New Appointments
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene therapy and oncology, joins the Company as Senior Vice President of Immunogenetics. Dr. Morgan brings to...
Sep 10, 2018 01:58 pm ET
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the U.S. patent...
Aug 27, 2018 04:01 pm ET
Editas Medicine Announces Transition of Chief Medical Officer
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D., will be stepping down from the Company at the end of the year. A search is underway to find a successor...
Aug 27, 2018 07:50 am ET
Analysis: Positioning to Benefit within Editas Medicine, Alcoa, MaxLinear, Real Goods Solar, NII, and Preformed Line Products — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Editas Medicine, Inc. (NASDAQ:EDIT), Alcoa Corp. (NYSE:AA), MaxLinear, Inc...
Aug 16, 2018 04:01 pm ET
Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration process for EDIT-101. The NIH...
Aug 06, 2018 04:05 pm ET
Editas Medicine Announces Second Quarter 2018 Results and Update
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the second quarter ended June 30, 2018, and provided an update on recent achievements and upcoming events. “During the second quarter, we...
Aug 06, 2018 04:01 pm ET
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
DUBLIN and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.
Aug 06, 2018 04:01 pm ET
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited...
Jul 30, 2018 04:02 pm ET
Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, August 6, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of...
Jun 21, 2018 08:10 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within TrustCo Bank Corp NY, Highwoods Properties, Enova International, Editas Medicine, United Insurance, and Cutera — New Research Emphas
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of TrustCo Bank Corp NY (NASDAQ:TRST), Highwoods Properties, Inc. (NYSE:HIW),...
Jun 13, 2018 09:00 am ET
Editas Medicine to Participate in The JMP Securities Life Sciences Conference
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20, 2018.  Details...
May 18, 2018 05:00 pm ET
Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that EDIT-101 was well-tolerated when administered to non-human primates (NHP) via subretinal injection. EDIT-101...
May 08, 2018 08:00 am ET
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:00 a.m....
May 03, 2018 04:01 pm ET
Editas Medicine Announces First Quarter 2018 Results and Update
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the first quarter ended March 31, 2018, and provided an update on recent achievements and upcoming events. “We made steady progress in...
Apr 30, 2018 01:30 pm ET
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Oral presentation of tolerability and immunogenicity data from a study of EDIT-101 following subretinal injection in non-human primates
Apr 30, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agilysys, Inc. (NASDAQ:AGYS), Editas Medicine, Inc....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.